Acrivon Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Acrivon Therapeutics, Inc. (ACRV) had Debt Securities, Available-for-sale, Amortized Cost of $48.58 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Credit Losses › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $48.58M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $63.67M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $76.97M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $98.84M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $48.58M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $63.67M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $76.97M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $98.84M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $105.62M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $125.39M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $144.30M 10-K · filed 2026-03-19 |
| 2024-09-30 | $158.65M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $174.44M 10-Q · filed 2024-08-13 |
| 2023-12-31 | $91.53M 10-K · filed 2025-03-27 |
| 2023-09-30 | $112.53M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $113.31M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $131.99M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $140.21M 10-K · filed 2024-03-28 |
| 2022-09-30 | $44.88M 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |